Company Overview and News

Viking Mines has an acquisition update to reveal

Viking Mines (ASX:VKA) has been granted a trading halt by the ASX this morning, pending an update in relation to its proposed Argo Group acquisition transaction.
Upvote Downvote

Viking Mines in a trading halt pending meeting outcome

Viking Mines (ASX:VKA) has been granted a trading halt by the ASX, pending the outcome of a shareholder meeting to be held today.
Upvote Downvote

Viking Mines shares ride higher on lithium potential in Thailand

Viking Mines (ASX:VKA) has identified a second parallel lepidolite pegmatite trend at the Reung Kiet (RK) Lithium Project in Thailand, substantially increasing the prospectivity of the project.
Upvote Downvote

Viking Mines Ltd bags $1.27M to explore lithium in Thailand

Funds raised pursuant to the placement will be used primarily to accelerate exploration of the company’s newly acquired Reung Kiet lithium project located in southern Thailand. The project contains two drill-ready pegmatites identified over a 3‐4 kilometre strike within a combined prospective trend of 10+ kilometres. The Reung Kiet pegmatite is over 1 kilometre long and up to 20 metres wide with the lepidolite having a reported grade of 3% lithium.
Upvote Downvote

Viking Mines Ltd heads to market

The halt will remain in place until the opening of trade on Thursday 24th November 2016, or earlier if an announcement is made to the market.
Upvote Downvote

Viking Mines banks US$2M from Ghana gold asset sale

Viking Mines (ASX:VKA) has banked a very handy US$2 million as part of the sale proceeds for its Akoase gold project in Ghana. Transfer of the licenses to the buyer of the West African project will commence and the $2 million proceeds are non-refundable. Government approvals are expected in due course. However, there are further cash proceeds to flow to Viking of US$6 million once Ministerial approvals for the transfer of the tenements are received.
Upvote Downvote

Trading Halt

Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

2018-04-25 - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

2018-04-25 - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...